Remember meForgot password?
    Log in with Twitter
Press Release

Scot Buchanan Appointed as Therigy's Vice President of Biotech and Specialty Services

Thirty-Year Biotechnology and Pharmacy Veteran Joins Therigy Team in Aligning Strategies, Relationships, and Technology to Maximize Stakeholder Outcomes

MAITLAND, FLORIDA - February 24, 2017 - (

​​​​​As specialty pharmacy continues to evolve with access to new medications, major mergers and acquisitions, accreditation changes, and an influx of new healthcare organizations entering the marketplace, the industry is reaching new heights in growth potential. This growth makes the alignment of biotech and specialty therapy strategies, relationships, and technology more important than ever before for delivering the best possible patient and business outcomes. Therigy®, the leader in specialty pharmacy consulting and developer of TherigySTM™, the pharmacy industry’s leading specialty therapy management software platform, understands this and has appointed biotech and pharmacy veteran, Scot Buchanan, as its Vice President of Biotech and Specialty Services.

In his role at Therigy, Buchanan is responsible for the management of pharma-facing business activities, which includes strategic direction of biopharma opportunities, oversight of pharma operations, pharma consulting services, business and market development, and pharma data product and service line development.

“From our earliest years in specialty pharmacy, Therigy has always recognized the importance of aligning biotech strategies and best practices, industry relationships, and technology in specialty pharmacy. These areas of expertise must be integrated to successfully harness specialty pharmacy growth, and enhance patient and business outcomes,” said Russel Allinson, RPh, MS, Therigy’s CEO and Chief Clinical Officer. “With Scot, Therigy has gained a seasoned veteran in all of these areas, who has the vision and the proven background to cultivate and implement these practices and relationships, all of which creates more value for all of our specialty pharmacy stakeholders.”

Buchanan joined Therigy as a 30-year veteran in the biotechnology and pharmacy industry. Prior to his appointment at Therigy, he served as Vice President of Manufacturer Relations at AmerisourceBergen. There, he directed the company’s enterprise-wide account management team to drive growth in partnership opportunities with pharmaceutical manufacturers. This growth included the development of cross-enterprise opportunities for specialty distribution, specialty pharmacy, full-line wholesaling, and variety of patient and consulting services. Before this, as Vice President of Supply Chain Strategy, Buchanan was responsible for product sourcing negotiations, all while growing new and existing business for the company’s Specialty Group. In addition to his tenure with AmerisourceBergen, Buchanan served in business development and sales leadership roles at CVS Caremark, AstraZeneca, and Merck.

Buchanan earned his Bachelor of Arts degree from Baylor University with an emphasis on business. 

About Therigy

Therigy is the trusted source for innovative, best-in-class software and expert consulting services to the specialty pharmaceutical market. Clients leverage Therigy’s solutions, data, and insights to achieve clinical and economic success by aligning strategy, technology, and people. Learn more about Therigy at Follow Therigy on LinkedIn and Twitter.

About TherigySTM

TherigySTM is used by leading specialty pharmacies to provide superior care and therapy-specific clinical support, maximize adherence, and improve outcomes.  The application allows for accurate and reliable data collection and outcomes reporting.  The product easily integrates with pharmacy dispensing systems.  Most importantly, Therigy has configured more than 253 clinical assessments into TherigySTM to provide a turnkey application that requires little if any additional clinical development by the subscriber. To our knowledge, TherigySTM is the only pharmacy care management system on the market which is pre-configured with clinical content and for which the subscription price includes regular releases of new content for new drugs, new indications, and changes to prescribing information.  In addition, Therigy has created the capability for easy customization of content and even complete protocols by the subscriber.

Related Links

Press Release Service by

Original Source: Scot Buchanan Appointed as Therigy's Vice President of Biotech and Specialty Services
Latest News
Top News